Six Misconceptions about Parkinson’s Support Groups

By Nancy Ryerson

After a Parkinson’s disease (PD) diagnosis, you may feel isolated from friends and family who aren’t going through the same experience. Meeting with others living with the disease through a support group can help you feel more connected, and introduce you to local resources you may not be familiar with, too.

Support groups are not one size fits all, however, and it may take a few tries before you find the right match. If you’re hesitant to try one out, read these experiences our community shared. Many people who are apprehensive about joining support groups later find them to be an integral part of life with the disease.

Misconception: Support groups are all business.

Reality: Meetings often feature a speaker and an informative discussion, but many have fun at meetings, too. Several commenters shared that as organizers, they also joke around and enjoy the group’s company. Good food and drink help, of course.

Read more at the Fox Feed Blog

2017 Alabama Parkinson’s Fighter Walk

The Parkinson’s Association of Alabama is excited to announce that the 2017 Alabama Parkinson’s Fighter Walk is Saturday, March 4 @ 9 am at the Samford University Track on Lakeshore Parkway in Homewood, AL. Proceed benefit research towards a cure for Parkinson’s disease.

We encourage PD patients, caregivers, and loved ones to attend. To register online or obtain additional information about this great event, visit: ALABAMA PARKINSON’S FIGHTER WALK.

New Ruling Supports Veterans with Parkinson’s Disease

By Allyse Falce

On January 12 the U.S. Department of Veterans Affairs (VA) made it easier for certain former service members with Parkinson’s disease (PD) to receive disability benefits. The decision applies to individuals who were exposed to contaminants at Camp Lejeune and later developed PD.

The Foundation’s Unified Parkinson’s Advocacy Council, comprising representatives from state, regional and national PD organizations who gather field-wide input on community policy priorities, sent a letter to the VA last October advocating in support of this decision.

This change will widen access to benefits that can improve quality of life, and it acknowledges evidence linking environmental exposures to Parkinson’s disease.

Read the Council’s letter to the VA.

Learn more about the VA’s decision.

Source: Fox Feed Blog

New Dyskinesia Drug Advances to Final Stage of FDA Review Process

By Kat McCarrick

Last week, the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for a dyskinesia therapy. Dyskinesia — characterized by uncontrolled, involuntary movements — can be a side effect of the prolonged use of levodopa, the gold standard treatment for Parkinson’s motor symptoms. The results of the FDA review will be announced by August, and if the medication is approved, it would be the first and only available therapy specifically designed to target levodopa-induced dyskinesia.

Developed by Adamas Pharmaceuticals, the drug is an extended-release formulation of amantadine (ADS-5102) that is taken once daily at bedtime. Compared with a shorter-acting form of amantadine already on the market, this new therapy is intended to control symptoms when they are most prevalent (during the day), while not interfering with sleep.

The NDA submitted in October includes a report on safety and efficacy outcomes from three placebo-controlled trials. These trials measured patient response to the drug using the Unified Dyskinesia Rating Scale, a tool supported by The Michael J. Fox Foundation.

Read more about dyskinesia.

Learn about MJFF’s investment in dyskinesia research.

Source: Fox Feed Blog